271 related articles for article (PubMed ID: 33341911)
1. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
5. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[TBL] [Abstract][Full Text] [Related]
6. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
7. Prediction Models for Intravenous Immunoglobulin Non-Responders of Kawasaki Disease Using Machine Learning.
Miyagi Y; Iwashima S
Clin Drug Investig; 2024 Jun; 44(6):425-437. PubMed ID: 38869717
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
9. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
10. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
11. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
Yoshikane Y; Okuma Y; Miyamoto T; Hashimoto J; Fukazawa R; Kato T; Takeda A; Suda K; Matsushita T; Hiroe M; Imanaka-Yoshida K
Pediatr Rheumatol Online J; 2021 Jun; 19(1):82. PubMed ID: 34090475
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
14. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y; Inuzuka R; Hayashi T; Shindo T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Oka A
Pediatr Int; 2016 Mar; 58(3):180-184. PubMed ID: 26222760
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
Miyata K; Miura M; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H
Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007191. PubMed ID: 33541111
[TBL] [Abstract][Full Text] [Related]
16. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Inoue Y; Okada Y; Shinohara M; Kobayashi T; Kobayashi T; Tomomasa T; Takeuchi K; Morikawa A
J Pediatr; 2006 Sep; 149(3):336-341. PubMed ID: 16939743
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
Jaggi P; Wang W; Dvorchik I; Printz B; Berry E; Kovalchin JP; Texter K; Ramilo O; Burns JC; Tremoulet AH
Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T; Kato I; Shiohama T; Abe K; Anzai S; Takeda N; Yamaguchi KI; Kanazawa M; Kurosaki T
Pediatr Int; 2011 Oct; 53(5):729-735. PubMed ID: 21342358
[TBL] [Abstract][Full Text] [Related]
19. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
[TBL] [Abstract][Full Text] [Related]
20. Predicting IVIG resistance in UK Kawasaki disease.
Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
